The review concluded that aspirin was effective for prevention of colorectal adenomas in individuals with a history of such lesions. Limited reporting of several aspects of the review means the authors' conclusions should be interpreted with caution.
To investigate whether aspirin reduced the risk of colorectal adenomas.
Searching
MEDLINE and Web of Science were searched. Search terms were reported. Colleagues were consulted to help identify unpublished studies.
Study selection
Double-blinded randomised controlled trials (RCTs) of aspirin (any dose given for at least one year) as a chemopreventive agent for sporadic large-bowel adenomas were eligible. Studies had to be placebo-controlled. Patients with familial adenomatous polyposis were excluded. Colorectal polyp status at baseline had to be assessed with complete colonoscopy with no polyps knowingly left in the bowel. Colorectal polyp occurrence after randomisation had to be assessed by colonoscopic follow-up. The primary outcome was occurrence of any colorectal adenoma.
The mean age of included participants was around 58 years. Approximately 60% of patients were male. Studies recruited patients between 1993 and 2001. Half of the trials studied low-dose aspirin (81mg/d or 160mg/d). All trials studied high-dose aspirin (300mg/d or 325 mg/d). Treatments were given for three or four years.
The authors did not state how many reviewers selected studies.
Assessment of study quality
The authors did not state that they assessed study quality and verified or checked the integrity of the data.
Data extraction
Participant-level data from each trial were obtained from individual trial authors in order to calculate risk ratios (RR) and absolute risk reductions with 95% confidence intervals (CI).
The authors did not state how many reviewers performed data extraction.
Methods of synthesis
Data were pooled by meta-analysis using a random-effects model. Only data from patients with at least one follow-up colonoscopy were analysed. Statistical heterogeneity was assessed using Cochran's Q and I 2 . Predefined subgroup analyses examined age, gender, body mass index (BMI), family history of colorectal cancer, number of lifetime adenomas and presence of advanced lesions at baseline. Effects of follow-up time point and dose were explored.
Results of the review
Four RCTs (n=2,967 participants, range 272 to 1,121) were included. Median follow-up was around 33 months. Mean treatment compliance rates ranged between 69% and 92%.
There was a statistically significant reduction in risk of any adenoma for aspirin (any dose) compared with placebo
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Page: 1 / 3 (RR 0.83, 95% CI 0.72 to 0.96, I 2 =41.5%; four RCTs). The benefit was significantly better for lower doses than higher doses (RR 1.18, 95% CI 1.01 to 1.37; two RCTs). For advanced lesions, the pooled risk ratio was 0.72 (95% CI 0.57 to 0.90, I 2 =0%; four RCTs). The largest reduction in risk for all adenomas occurred during the first year of follow-up (RR 0.62, 95% CI 0.48 to 0.81; three RCTs). Aspirin had no effect on risk beyond 38 months (RR 0.99, 95% CI 0.78 to 1.26; four RCTs).
No statistically significant effect modification was found for any of the baseline variables studied, although the effect of aspirin (any dose) on advanced lesions was greater in those with a family history of colorectal cancer (RR 0.53, 95% CI 0.33 to 0.83) than in those without (RR 0.92, 95% CI 0.67 to 1.28). There were no differences between groups in adverse events (reported in three RCTs) for mortality, myocardial infarction, major bleeding and all-site invasive cancer, but there was a statistically significantly higher rate of strokes (most of which were thought to be ischaemic) among aspirin-treated participants than among those who received placebo. In the three studies that reported incidence of colorectal cancer (in patients with no history of colorectal cancer) there was no significant difference between treatment groups. Further results were reported.
